Boron neutron capture therapy of brain tumors: An emerging therapeutic modality

Neurosurgery

Volumn 44, Issue 3, 1999, Pages 433-451

  Barth, Rolf F ^a,g   Soloway, Albert H ^a   Goodman, Joseph H ^b   Gahbauer, Reinhard A ^c   Gupta, Nilendu ^d   Blue, Thomas E ^e   Yang, Weilian ^f   Tjarks, Werner ^a  

^a Department of Pathology ^*  (United States)

^b The Ohio State University   (United States)

^c Division of Neurosurgery   (United States)

^d Department of Internal Medicine Division of Medical Oncology Starling Loving Hall   (United States)

^e College of Pharmacy ^*  (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g OHIO STATE UNIVERSITY   (United States)

Author keywords

Boron neutron capture therapy; Brain tumors

Indexed keywords

4 BORONOPHENYLALANINE; AMINO ACID; BOROCAPTATE; BORON 10; BORON DERIVATIVE; EPIDERMAL GROWTH FACTOR; LIPOSOME; NUCLEOSIDE; PHENYLALANINE DERIVATIVE; POLYAMINE; PORPHYRIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; ELECTRON ACCELERATOR; GLIOBLASTOMA; MICRODOSIMETRY; NEUROSURGERY; NEUTRON CAPTURE THERAPY; NUCLEAR REACTOR; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOBIOLOGY; RADIOSENSITIVITY; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0032979995     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199903000-00001     Document Type: Article

References (155)

1. Asbury AK, Ojemann RG, Nielson SL, Sweet WH: Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 31: 278-303, 1972.
2. Barth RF: Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F9S, RG2 (D74), RT-2, and CNS-1 gliomas. J Neurooncol 36: 55-66, 1998.
3. Barth RF, Adams DM, Soloway AH, Alam F, Darby MV: Boronated starburst dendrirner-monodonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem 558-66, 1994.
4. Barth RF, Soloway AH, Brugger RM: Boron neutron capture therapy of brain tumors: Past history, current status and future potential. Cancer Invest 14: 534-550, 1996.
5. Barth RF, Yang W, Moeschberger ML, Goodman JH, Bartus RT: Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analogue Cereport (receptor-mediated permeabilizer-7). Neurosurgery 44: 351-360, 1999.
6. Barth RF, Yang W, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, Goodman JH, Soloway AH: Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res 57: 1129-1136, 1997.
7. Barth RF, Yang W, Soloway AH, Goodman JH: Alternative approaches for the delivery of boron containing agents to brain tumors, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Chemistry and Biology. Amsterdam, Elsevier, 1997, vol 2, pp 216-224.
8. Beach JL, Schroy CB, Ashtari M, Maruyana Y: Boron neutron' capture enhancement of Cf-252 brachytherapy. Int J Radiât Oncol Biol Phys 18: 1421-1427, 1990.
9. 10B double resonance. Magn Reson Med 32: 170-174, 1994.
10. Berger MS: Malignant astrocytomas: Surgical aspects. Semin Oncol 21: 172-185, 1994.
11. Black KL: Biochemical opening of the blood-brain barrier. Ad v Drug Delivery Rev 15: 37-52, 1995.
12. Black KL, Cloughesy T, Huang SC, Gobin YP, Zhou Y, Grous J, Nelson G, Farahani K, Höh CL, Phelps M: Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 86: 603-609, 1997.
13. Blackburn BW, Klinkowstein RE, Yanch JC, Song H, Howard W: Development of a high-powered, water-cooled beryllium target for the production of neutrons in a high-current tandem accelerator, in Duggan JL, Morgan IL (eds): Application of Accelerators in Researcli and Industry. Woodbury, American Institute of Physics, 1997, vol 2, pp 1293-1296.
14. Blasberg RG, Groothuis DR: Chemotherapy of brain tumors: Physiological and pharmacokinetic considerations. Semin Oncol 13: 70-82, 1986.
15. Blue TE, Gupta N, Wollard JE: A calculation of the energy dependence of the RBE of neutrons. Phys Med Biol 38: 16931712, 1993.
16. Blue JW, Roberts WK, Blue TE, Gahbauer RA, Vincent JA: A study of proton accelerators for neutron capture therapy, in Hatanaka H (ed): Neutron Capture Tlierapy. Niigata, Niskimura Co., 19S5, pp 147-158.
17. Brugger RM, Less TD: A progress report, in Hatanaka H (ed): Neutron Capture Tlierapy. Niigata, Nishimura Co., 1986, pp 110-116.
18. Brugger RM, Constantine G, Harling OK, Wheeler FJ: Rapporteur's report, in Harling OK, Bernard JA, Zamenhof RG (eds): Neutron Beam Design, Development, and Performance for Neutron Capture Tlierapy. New York, Plenum Press, 1990, pp 249-258.
19. Bucholz TA, Laramore GE, Wootton P, Livesey JC, Wilbur DS, Risler R, Phillips M, Jacky J, Griffin TW: Enhancement of fast neutron beams with boron neutron capture therapy: A mechanism for achieving a selective, concomitant tumor boost. Acta Oncol 33: 307-313, 1994.
20. Cai J, Soloway AH, Earth RF, Adams DA, Hariharan JR, Wyzlic IM, Radcliff K: Boron-containing polyamines as DNA targeting agents for neutron capture therapy of brain tumors: Synthesis and biological evaluation. J Med Chem 40: 3887-3896, 1997.
21. Capala J, Earth RF, Bendayan M, Lauzon M, Adams D, Soloway AH, Carlsson J: Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem 7: 7-15, 1996.
22. Carlsson J, Gedda L, Grönvik C, Hartman T, Lindström A, Lindström P, Olsson P, Fönten J, Sjöberg S, Westermark B: Strategy for boron neutron capture therapy against brain tumor cells with over-expression of the epidermal growth factor receptor. Int J Radial Oncol Biol Phys 30: 105-115, 1993.
23. Christensen RN, Guo P, Blue TE, Button GL, Bahney RH, Worthy K: Critical heat flux experiment for BNCT heat removal system design. Trans Am Nucl Soc 64: 647, 1991.
24. Clendenon NR, Earth RF, Gordon WA, Goodman JH, Alam F, Staubus AE, Boesel CP, Yates AJ, Moeschberger ML, Fairchild RG, Kalef-Ezra JA: Boron neutron capture therapy of a rat glioma. Neurosurgery 26: 47-55, 1990.
25. Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM, Liu HB: Neutron capture therapy of the 9L gliosarcoma using the p-boronophenylalanine-fructose complex. IntJ Radiât Oncol Biol Phys 30: 643-652, 1994.
26. Coderre JA, Chanana AD, Joel DD, Elowitz EH, Micca PL, Nawrocky MM, Chadha M, Gebbers J-O, Shady M, Peress NS, Slatkin DN: Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: Boron concentration correlates with tumor cellularity. Radiât Res 149: 163-170, 1988.
27. Coderre JA, Elowitz EH, Chadha M, Bergland R, Capala J, Joel DD, Liu HB, Slatkin DN, Chanana AD: Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: Trial design and early clinical results. J Neurooncol 33: 141-152, 1997.
28. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach J, Chang CH, Rotman M, Asbell SO, Kirsch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993.
29. Dahlborg SA, Henner WD, Crossen JR, Tableman M, Petrillo A, Braziel R, Neuwelt EA: Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2: 166-174, 1996.
30. Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA: The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 4: 110-124, 1998.
31. Davis LW: Presidential address: Malignant glioma-A nemesis which requires clinical and basic investigation in radiation oncology. Int J Radiât Oncol Biol Phys 16: 1355-1365, 1989.
32. Davis MA, Little JB: Relative biological effectiveness of the 10B (n, a) 7Li reaction in HeLa cells. Radiât Res 43: 534-553, 1970.
33. Davis FG, Freeks S, Grutsch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology and end results (SEER) data 19731991. J Neurosurg 88: 1-10, 1998.
34. Deutsch OL, Murray BW: Monte Carlo dosimetry calculations for boron neutron capture therapy in the treatment of brain tumors. Nucl Technol 26: 320-339, 1975.
35. De Wolde H, Pruim J, Mastik MF, Koudstaal J, Molenaar WM: Proliferative activity in human brain tumors: Comparison of histopathology and L-[1-"C] tyrosine PET. J Nucl Med 38: 13681374, 1997.
36. Elliott PJ, Hayward NJ, Dean RL, Bartus RT: Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology 33: 205-208, 1996.
37. Elliott PJ, Hayward NJ, Dean RL, Blunt DG, Bartus RT: Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 56: 3998-4005, 1996.
38. Elliott PJ, Hayward HJ, Huff MR, Nagle TL, Black KL, Bartus RT: Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy. Exp Neurol 141: 214-224, 1996.
39. Elowitz EH, Bergland RM, Coderre JA, Joel DD, Chadha M, Chanana AD: Biodistribution of f)-boronophenylalanine in patients with glioblastomas multiforme for use in boron neutron capture therapy. Neurosurgery 42: 463-469, 1998.
40. Elowitz EH, Chadha M, Iwai J, Coderre JA, Joel DD, Slatkin DN, Chanana AD: A Phase I/trial of boron neutron capture therapy (BNCT) for glioblastoma multiforme using intravenous boronophenylalanine-fructose complex and epithermal neutrons: Early clinical results, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Medicine and Physics. Amsterdam, Elsevier, 1997, vol 1, pp 56-64.
41. Fallot T, Magdelena TH, Mady E, Stasiecki P, Fohann D, Gropp P, Poisson M, Delttre JY: A Phase I study of an antiepidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 39: 478-483, 1996.
42. Farr LE, Haymaker W, Konikowski T, Lippincott SW: Effects of alpha particles randomly induced in the brain in the neutroncapture treatment of intracranial neoplasms. Int J Neurol 3: 564576, 1962.
43. Farr LE, Sweet WH, Robertson JS, Foster CG, Locksley HB, Sutherland L, Mendelsohn ML, Stickley EE: Neutron capture therapy with boron in the treatment of glioblastoma multiforme. AJR Am J Roentgenol 71: 279-293, 1954.
44. Feakes DA, Shelly K, Hawthorne M: Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc Natl Acad Sci USA 92: 1367-1370, 1995.
45. Fenstermacher CD, Cowles AL: Theoretic limitation of intracarotid infusion in brain tumor chemotherapy. Cancer Treat Rep 61: 519-526, 1977.
46. Furnari FB, Su Huang H-J, Cavenee WK: Genetics and malignant progression of human brain tumors, in Ponder BA], Cavenee WK, Solomon E (eds): Cancer Surveys: Genetics and Cancer-A Second Look. Plainview, Cold Spring Harbor Laboratory Press, 1995, vol 25, pp 233-275.
47. Gabel D, Foster S, Fairchild RG: The Monte Carlo simulation of the biological effect of the IOB (n, a) 7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiât Res 111: 25-36, 1987.
48. Gahbauer RA, Fairchild RG, Goodman JH, Blue TE: Can relative biological effectiveness be used for treatment planning in boron neutron capture therapy? in Breit A (ed): Tumor Response Monitoring and Treatment Planning. Berlin, Springer-Verlag, 1992, pp 755-758.
49. Gavin PR, Kraft SL, Huiskamp R, Coderre JA: A review: CNS effects and normal tissue tolerance in dogs. J Neurooncol 33: 7180, 1997.
50. Goudgaon NM, Fulcrand-El Kattan G, Schinazi RF: Boron containing pyrimidines, nucleotides and oligonucleotides for neutron capture therapy. Nucleosides Nucleotides 13: 849-380, 1994.
51. Greig NH: Drug delivery to the brain by blood-brain barrier circumvention and drug modification, in Neuwelt EA (ed): Implications of the Blood-Brain Barrier and Its Manipulation. New York, Plenum Medical Book Co., 1989, vol 1, pp 311-367.
52. Groothuis DR, Warkne PC, Molnar P, Lapin GD, Mikhael MA: Effect of hyperosmotic blood-brain barrier disruption and transcapillary transport in canine brain tumors. J Neurosurg 72: 441449, 1990.
53. Grusell E, Condé B, Larsson B, Rönnquist T, Sornsuntisook O, Crawford J, Reist H, Dahl B, Sjöstrand NG, Rüssel G: The possible use of a spallation neutron source for neutron capture therapy with epithermal neutrons, in Harling OK, Bernard JA, Zamenhof RG (eds): Neutron Beam Design, Development, and Performance for Neutron Capture Therapy. New York, Plenum Press, 1990, pp 249-258.
54. Gupta N, Gahbauer RA, Blue TE, Wambersie A: Dose prescription in boron neutron capture therapy. Int J Radiât Oncol Biol Phys 28: 1157-1166, 1994.
55. Halperin EC, Burger PC, Bullard DE: The fallacy of the localized supratentorial malignant glioma. Int J Radiât Oncol Biol Phys 15: 505-509, 1988.
56. Harker YD, Harmon JF, Seamans J, Serrano S, Trammel W, Yost L, Zhou X-L, Hamm RW: Accelerator neutron sources for NCT using near threshold charged particle reactions. Proceedings of the International Conference: Neutrons and Their Applications, in Proc SPIE 2867: 80-83, 1997.
57. Harling OK, Moulin D, Chabeuf JM, Solares GR: On line beam monitoring for boron neutron capture therapy at the MIT Research Reactor, in Mishima Y (ed): Cancer Neutron Capture Therapy. New York, Plenum Press, pp 261-269, 1996.
58. Hatanaka H: Boron neutron capture therapy for brain tumors, in Karin ABMF, Laws E (eds): Glioma. Berlin, Springer-Verlag, 1991, pp 233-249.
59. Hatanaka H, Kamano S, Amano K, Hojo S, Sano K, Egawa S, Yasukochi H: Clinical experience of boron-neutron capture therapy for gliomas: A comparison with conventional chemo-immunoradio-therapy, in Hatanaka H, (ed): Boron Neutron Capture Therapy for Tumors. Niigata, Nishimura Co., 1986, pp 349-378.
60. Hawthorne MF: The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed Engl 32: 950-984, 1994.
61. Hill JS, Kahl SB, Kaye AH, Stylli SS, Koo M-S, Gonzales MF, Verdaxis NJ, Johnson CI: Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc Natl Acad Sci U S A 89: 1785-1789, 1992.
62. Hill JS, Kahl SB, Stylli SS, Nakamura Y, Koo M-S, Kaye AH: Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated phophyrin photosensitizer. Proc Natl Acad Sci U S A 92: 12126-12130, 1995.
63. Javid M, Brownell GL, Sweet WH: The possible use of neutron capture isotopes such as boron-10 in the treatment of neoplasms: II-Computation of the radiation energy and estimates of effects in normal and neoplastic brain. J Clin Invest 31: 603-610, 1952.
64. Kabalka GW, Tang C, Bendel P: The role of boron MRI in boron neutron capture therapy. J Neurooncol 33: 153-161, 1997.
65. Kahl SB, Koo M-S: Synthesis of tetrakis-carborane-carboxylate esters of 2, 4-bis-(a, /3-dihydroxyethyl)-deuteroporphyrin IX. J Chem Soc Chem Comm 1769-1771, 1990.
66. Kahl SB, Pate DW, Waunschel LA: Low density lipoprotein reconstitution with alkyl and aryl carboranes, in Soloway AH, Earth RF, Carpenter DE (eds): Advances in Neutron Capture Therapy. New York, Plenum Press, 1993, pp 399-102.
67. Kalend AM, Bloomer WD, Epperly W: Dosimetric consequences of 10B (n, a) 7Li reaction occurring at the cellular membrane. Int J Radial Oncol Biol Phys 31: 171-178, 1995.
68. Kiger WS III, Harling OK: Design studies for the MIT fission converter beam, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Medicine and Physics. Amsterdam, Elsevier, 1997, vol 1, pp 403-407.
69. Kim J, Yanch JC, Wilson MJ: Californium based epithermal neutron beams for neutron capture therapy, in Soloway AH, Earth RF, Carpenter DE (eds): Advances in Neutron Capture Therapy. New York, Plenum Press, 1993, pp 131-134.
70. Kobayashi T, Kanda K: Analytical calculation of boron-10 dosage in cell nucleus for neutron capture therapy. Radial Res 91: 77-94, 1982.
71. Kobayashi T, Kanda K: Microanalysis system of ppm-order 10B concentrations in tissue for neutron capture therapy by prompt gamma-ray spectrometry. Nucl Inslr Melh 204: 96-103, 1983.
72. Kwan JW, Anderson OA, Reginato LL, Vella MC, Yu SS: Electrostatic quadrupole DC accelerators for BNCT applications, in ' Proceedings of First International Workshop on Accelerator-based Neutron Sources for Boron Neutron Capture Therapy, Jackson, WY, September 11-14, 1994. Idaho Falls, Idaho National Engineering Laboratory, 1995, pp 111-120.
73. Laramore GE, Spence AM: Boron neutron capture therapy (BNCT) for high grade gliomas of the brain: A cautionary note. Int J Radial Oncol Biol Phys 36: 241-246, 1996.
74. Laramore GE, Wootton P, Livesey JC, Wilbur DS, Risler R, Phillips M, Jacky J, Bucholz TA, Griffin TW, Brossard S: Boron neutron capture therapy: A mechanism for achieving a concomitant tumor boost in fast neutron radiotherapy. Int J Radiât Oncol Biol Phys 28: 1135-1142, 1994.
75. Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Vol. I, Medicine and Physics, and Vol. II., Chemistry and Biology-Excerpta Medica. Amsterdam, Elsevier, 1997.
76. Liberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021-1029, 1995.
77. Liu L, Earth RF, Adams, D, Soloway AH, Reisfeld RA: Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Anticancer Res 16: 2581-2588, 1996.
78. Liu HB, Brugger RM, Rorer DC, Tichler PR, Hu JP: Design of a high-flux epithermal neutron beam using 231U fission plates at the Brookhaven Medical Research Reactor. Med Phys 21: 1624-1631, 1994.
79. Loeffler JS, Alexander E III, Hochberg FH, Wen PY, Morris JH, Schoene WC, Siddon RL, Morse RH, Black PMcL: Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radial Oncol Biol Phys 19: 1455-1462, 1990.
80. Matalka KZ, Barth RF, Staubus AE, Moeschberger ML, Coderre JA: Boron neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent. Radiât Res 137: 44-51, 1994.
81. Miley GH, Javedani JB, Gu YB, Satsangi AJ, Heck PF, Tzonev ID, Williams MJ, DelMedico SG, Nebel RA, Barnes DC, Turner L, Nadler JH, Sved J: The IEC: A novel source for boron neutron capture therapy, in Proceedings of the First International Workshop o Accelerator-based Neutron Sources for Boron Neutron Capture Therapy, September 11-14, 1994, Jackson, WY. Idaho Falls, Idaho National Engineering Laboratory, 1995, vol 1, pp 79-88.
82. Mishima Y (ed): Cancer Neutron Capture Tlierapy. New York, Plenum Press, 1996.
83. Mishima Y: Selective thermal neutron capture therapy of cancer cells using their specific metabolic activities-melanoma as prototype, in Mishima Y (ed): Cancer Neutron Capture Therapy. New York, Plenum Press, 1996, pp 1-26.
84. Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, Karashima T, Kobayashi K, Kanda K, Yoshino K: Treatment of malignant melanoma by single neutron capture treatment with melanoma-seeking 10B compound. Lancet 11: 388-389, 1989.
85. Miura M, Micca PL, Fisher CD, Gordon CR, Heinrichs JC, Slatkin DN: Evaluation of carborane-containing porphyrins as tumor targeting agents for boron neutron capture therapy. Br J Radiol 71: 773-781, 1998.
86. Miura M, Micca PL, Fisher CD, Heinrichs JC, Donaldson JA, Finkel GC, Slatkin DN: Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron capture therapy: Biodistribution and toxidty in tumor bearing mice. Int J Cancer 68: 114-119, 1996.
87. Morris GM, Coderre JA, Hopewell JW, Rezvani M, Micca PL, Fisher CD: Response of the central nervous system to fractionated boron neutron capture irradiation: Studies with borocaptate sodium. Int J Radial Biol 71: 185-192, 1997.
88. Moss RL, Aizawa O, Beynon D, Brugger R, Constantine G, Harling O, Liu HB, Watkins P: The requirements and development of neutron beams for neutron capture therapy of brain cancer. J Neurooncol 33: 27-40, 1997.
89. Moss RL, Casado J, Ravensberg K, Stecher-Radmussen F, Watkins P: The completed boron neutron capture therapy facility at the HFR Petten, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Medicine and Physics. Amsterdam, Elsevier, 1997, vol 1, pp 331-335.
90. Munday AD, Sriratana A, Hill JH, Kahl SB, Nagley P: Mitochondria are the functional intracellular target for photosensitizing boronated porphyrin. Biochem Biophys Acta 1311: 1-4, 1996.
91. Nakagawa Y, Hatanaka H: Boron neutron capture therapy: Clinical brain lumor studies. J Neurooncol 33: 105-115, 1997.
92. Neuwelt EA, Barnett PA: Blood-brain barrier disruption in the treatment of brain tumors: Animal studies, in Neuwelt EA (ed): Implications of the- Blood-Brain Barrier and Its Manipulation: Clinical Aspects. New York, Plenum Press, 1989, vol 2, pp 107-261.
93. Neuwelt EA, Frenkel EP: The challenge of the blood-brain barrier, in Neuwelt EA (ed): Implications of the Blood-Brain Barrier and Its Manipulation. New York, Plenum Press, 1989, vol 1, pp 1-24.
94. Niemkiewicz J, Blue TE: The use of removal diffusion theory to calculate neutron flux distributions for dose determination in boron neutron capture therapy, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Tlierapy: Medicine and Physics. Amsterdam, Elsevier, 1997, vol 1, pp 275-278.
95. Nigg DW (ed): Proceedings of the First International Workshop on Accelerator-based Neutron Sources for Boron Neutron Capture Therapy, September 11-14, 1994, Jackson, WY. Idaho Falls, Idaho National Engineering Laboratory, 1995 and 1996, vol 1 and 2.
96. Nigg DW, Mitchell, HE, Harker YD, Yoon WY, Jones JL, Harmon JF: Epithermal photoneutron source studies for BNCT, in Proceedings of the First International Workshop on Accelerator-based Neutron Sources for Boron Neutron Capture Therapy, September 11-14, 1994, Jackson, WY. Idaho Falls, Idaho National Engineering Laboratory, 1996, vol 2, pp 373-388.
97. Nigg DW, Randolph PD, Wheeler FJ: Demonstration of threedimensional deterministic radiation transport theory dose distribution analysis for boron neutron capture therapy. Med Phys 18: 43-53, 1991.
98. Nigg DW, Wheeler FJ, Wessol DE, Capala J, Chadha M: Computational dosimetry and treatment planning for boron neutron capture therapy. J Neurooncol 33: 93-104, 1997.
99. Ozawa T, Afzal J, Wyrick BJ, Hu LJ, Lamborn KR, Bollen AW, Bauer WF, Fike JR, Phillips TL, Blakely EA, Kahl SB, Deen DF: In vivo evaluation of a boronated prophryin in malignant glioma models. Froc Am Assoc Cancer Res 39: 586, 1998 (abstr).
100. Pardridge WM: Drug delivery to the brain. J Cereb Blood Flow Metabol 17: 713-731, 1997.
101. Perry JR, DeAngelis LM, Schold SC Jr, Berger PC, Brem H, Brown MT, Curran WJ, Scott CB, Prados MD, Kaplan R, Cairncross JG: Challenges in the design and conduct of Phase brain tumor therapy trials. Neurology 49: 912-917, 1997.
102. Raaijmakers CP, Konijnenberg MW, Verhagen HW, Mijnheer BJ: Determination of dose components in phantoms irradiated with an epithermal neutron beam for boron neutron capture therapy. Med Phys 22: 321-329, 1995.
103. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chianh Y, McGarriey GJ, Muul LM, Katz D, Blaese RM, Oldfield EH: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3: 1354-1361, 1997.
104. Rapoport SI, Robinson PJ: A therapeutic role for osmotic opening of the blood-brain barrier: Re-evaluation of literature and of importance of source-sink relations between brain and tumor, in Johnson BB, Owman C, Widner H (eds): Pathophysiology of the Blood-Brain Barrier. Amsterdam, Elsevier, 1990, pp 167-181.
105. Riva P, Arista A, Franceschi G, Frattarelli M, Sturiale A, Riva N, Casi M, Rossitti R: Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: Comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 55: 5952-5956, 1995.
106. Rong F-G, Soloway AH, Ikeda S, Ives DH: Synthesis and biochemical activity of hydrophilic carborane-containing pyrimidine nucleosides as potential agents for DNA incorporation and BNCT. Nucleosides Nucleotides 16: 379-101, 1997.
107. Rydin RA, Deutsch OL, Murray BW: The effect of geometry on capillary wall dose for boron neutron capture therapy. Phys Med Biol 21: 134-138, 1976.
108. Sauervvein W: The clinical project at HFR Fetten: A status report, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Medicine and Physics. Amsterdam, Elsevier, 1997, vol 1, pp 77-84.
109. Sauerwein W, Rassow J, Mijnheer B: Considerations about specification and reporting of dose in BNCT, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Tlierapy: Medicine and Physics. Amsterdam, Elsevier, 1997, vol 1, pp 531-534.
110. Savolainen S, Auterinen I, Kallio M, Kärkkäinen M, Kosunen A, Aschan C, Benczik J, Färkkilä M, Seppälä T, Kaita K, Kulvik M, Ryynänen P, Seppälä T, Seren T, Tanner V, Toivonen M, Vähätalo J, Ylä-Mella H: The Finnish boron neutron capture therapy program: An overview of scientific projects, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Medicine and Physics. Amsterdam, Elsevier, 1997, pp 342-347.
111. Scobie M, Threadgill MD: Synthesis of carborane-containing nitroimidazole compounds via mild 1, 3-dipolar cycloaddition. J Chem Soc Chem Comm 13: 939-941, 1992.
112. Shapiro WR: Is there a therapeutic role for osmotic breaching of the blood brain barrier? Ann Neurol 24: 680-682, 1987 (letter).
113. Shapiro WR: Bias in uncontrolled brain tumor trials. Can J Neurol Sci 24: 269-270, 1997.
114. Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE: Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: A quantitative autoradiographic study. Cancer Res 48: 694-701, 1998.
115. Shefer RD, Klinkowstein RD, Yanch JC, Howard WB: Tandem electrostatic accelerators for BNCT, in Proceedings of the First International Workshop on Accelerator-based Neutron Sources for Boron Neutron Capture Therapy, September 11-14, 1994, Jackson, WY. Idaho Falls, Idaho National Engineering Laboratory, 1995, vol 1, pp 89-98.
116. Shelly K, Feakes DA, Hawthorne MF, Schmidt PG, Krisch TA, Bauer WF: Model studies directed toward the boron neutron capture therapy of cancer: Boron delivery to murine tumors with liposomes. Proc Nat Acad Sci U S A 89: 9039-9043, 1992.
117. Sjöberg S, Carlsson J, Ghaneolhosseini H, Gedda L, Hartman T, Malmquist L, Naeslund C, OIsson P, Tjarks W: Chemistry and biology of some low molecular weight boron compounds boron neutron capture therapy. J Neurooncol 33: 41-52, 1997.
118. Slatkin DN: A history of boron neutron capture therapy of brain tumors. Brain 114: 1609-1629, 1991.
119. Snyder HR, Reedy AJ, Lennarz WJ: Synthesis of aromatic boronic acids, aldehydo boronic acids and a boronic acid analog of tyrosine. J Am Chem Soc 80: 835-838, 1958.
120. Solares GR, Zamenhof RG: A novel approach to the microdosimetry of neutron capture therapy: Part 1-High resolution quantitative autoradiography applied to microdosimetry in neutron capture therapy. Radial Res 144: 50-58, 1995.
121. Soloway AH, Barth RF, Alam F, Carey WE: Delivery of boron-10 for neutron capture therapy by means of chemical compounds and antibodies, in Hatanaka H (ed): Boron Neutron Capture Therapy for Tumors. Niigata, Nishimura Co., 1986, pp 47-58.
122. Soloway AH, Hatanaka H, Davis MA: Penetration of brain and brain tumor: VII-Tumor-binding sulfhydryl boron compounds. J Med Chem 10: 714-717, 1967.
123. Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG: The chemistry of neutron capture therapy. Chem Rev 98: 1515-1562, 1998.
124. Sprizziri PG, Hill JH, Kahl SB, Ghiggino KP: Photophysics and intracellular distribution of a boronated porphyrin phototherapeutic agent. Photochem Photobiol 64575-983, 1996.
125. Sweet WH: Early history of development of boron neutron capture therapy of tumors. J Neurooncol 33: 19-26, 1997.
126. Sweet WH, Soloway AH, Brownell GL: Boron-slow neutron capture therapy of gliomas. Acta Radiol 1: 114-121, 1963.
127. Swenson DA: A new LINAC structure for the BNCT application, in Proceedings of the First International Workshop on Acceleratorbased Neutron Sources for Boron Neutron Capture Therapy, September 11-14, 1994, Jackson, WY. Idaho Falls, Idaho National Engineering Laboratory, 1995, pp 121-128.
128. Taghian A, Ramsay J, Allalunis-Turner J, Allalunis-Turner J, Budach W, Gioioso D, Pardo F, Pkunieff P, Blechen N, Urtasun R, Suit H: Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiât Oncol Biol Phys 25: 243-249, 1993.
129. Tamargo RJ, Langer R, Brem H: Interstitial drug delivery to the central nervous system using controlled release polymers: Chemotherapy for brain tumors. Methods Neurosci 21: 135-149, 1994.
130. Tjarks W, Gabel D: Boron containing thiouracil derivatives for neutron capture therapy of melanoma. J Med Chem 34315-319, 1991.
131. Tjuvajev JG, Macapinac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B: Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 35: 1407-1417, 1994.
132. Tolpin El, Wellum GR, Dohan FC, Kornblith PL, Zamenhof RG: Boron neutron capture therapy of cerebral gliomas: II-Utilization of the blood-brain barrier and tumor-specific antigens for the selective concentrations of boron in gliomas. Oncology 32: 223-246, 1975.
133. Utsumi H, Ichihashi M, Kobayashi T, Elkind MR: Sublethal and potential lethal damage repair on thermal neutron capture therapy. Pigment Cell Res 2: 337-342, 1989.
134. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41: 44-49, 1997.
135. van der Kogel AJ: Central nervous system radiation injury in small animal models, in Gutin PH, Leibel SA, Sheline GE (eds): Radiation Injury to the Nervous System. New York, Raven Press, 1991, pp 91-111.
136. Viola JJ, Agbaria R, Walbridge S, Oshiro EM, Johns DG, Kelley JA, Oldfield H, Ram Z: In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res 55: 1306-1309, 1995.
137. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H: Intrarumoral chemotherapy. Neurosurgery 37: 1128-1145, 1995.
138. Wang CK, Moore BR: Thick beryllium target as an epithermal neutron source for neutron capture therapy. Med Phys 21: 1633-1638, 1994.
139. Wang CK, Blue TE, Blue JW: A design study of an accelerator based neutron irradiation facility for boron neutron capture therapy. Strahlenther Onkol 165: 75-78, 1989.
140. Wang CK, Blue TE, Blue JW: A neutronic study of an acceleratorbased neutron irradiation facility for boron neutron capture, in ' Harling OK, Bernard JA, Zamenhof RG (eds): Neutron Beam Design Development and Performance for Neutron Capture Therapy. New York, Plenum Press, 1990, pp 271-280.
141. Wang CK, Blue TE, Gahbauer R: A neutronic study of an accelerator-based neutron irradiation facility for boron neutron capture. Nucl Technol 84: 93-107, 1989.
142. Wangler TP, Stovall JE, Bhatia IS, Wang CK, Blue TE, Gahbauer RA: Conceptual design of an RFQ accelerator based neutron source for boron neutron capture therapy. Presented at the Particle Accelerator Conference, Chicago, IL, March 20-23, 1989.
143. Wheeler FJ: Microdosimetric calculations of boron-drug compound factors for boron neutron capture therapy. Trans Am Nucl Soc 65: 147-148, 1992.
144. Wollard JE, Blue TE, Curran JF, Dobelbower MC, Busby HR: An alpha auradiographic technique for spatial quantification of 10B concentrations in tissues. Nucl Sci Engr 110: 96-103, 1992.
145. Wuu CS, Amols HI, Kliauga P, Reinstein LE, Saraf S: Microdosimetry for boron neutron capture therapy. Radiât Res 130: 355-359, 1992.
146. Wyzlic IM, Tjarks W, Soloway AH, Anisuzzaman AKM, Rong FG, Earth RF: Strategies for the design and synthesis of boronated nucleic acid and protein components as potential delivery agents for neutron capture therapy. Int J Radiât Oncol Biol Phys 28: 1203-1213, 1994.
147. Wyzlic IM, Tjarks W, Soloway AH, Perkins DJ, Burgos M, O'Reilly KP: Synthesis of carboranyl amino acids, hydantoins and barbiturates. Inorg Chem 35: 4541-4547, 1996.
148. Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A, Sakamoto K, Kayama T, Yoshimoto T: Radioresponse and prognosis of malignant glioma. Tohoku J Exp Med 167: 79-87, 1992.
149. Yanch JC, Zhou X-I, Shefer RE, Klinkowstein RE: Acceleratorbased epithermal neutron beam design for neutron capture therapy. Med Phys 19: 709-722, 1992.
150. Yang W, Earth RF, Adams DA, Soloway AH: Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res 57: 4333-4339, 1997.
151. Yang W, Earth RF, Carpenter DE, Moeschberger ML, Goodman JH: Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery 38: 985-992, 1996.
152. Yang W, Earth RF, Rotaru JH, Joel DD, Nawrocky MM, Goodman JH: Enhanced survival of glioma bearing rats following boron neutron capture therapy with osmotic blood-brain barrier disruption and intracarotid injection of boronophenylalanine. J Neurooncol 32: 59-70, 1997.
153. Yang W, Earth RF, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, Goodman JH, Soloway AH: Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int J Radiât Oncol Biol Phys 37: 663-672, 1997.
154. Zamenhof RG: Microdosimetry for boron neutron capture therapy: A review. J Neurooncol 33: 8-92, 1997.
155. Zamenhof RG, Solares GR, Kiger WS HI, Riley KJ, Busse PM, Fischer E, Norregaard T, Harling OK: Clinical treatment planning of subjects undergoing boron neutron capture therapy, in Larsson B, Crawford J, Weinreich R (eds): Advances in Neutron Capture Therapy: Chemistry and Biology. Amsterdam, Elsevier, 1997, vol 2, pp 614-620.